




RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022



Celldex Therapeutics Inc. Rank 21 of 50



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022



Celldex Therapeutics Inc. Rank 21 of 50

The relative strengths and weaknesses of Celldex Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celldex Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 343% points. The greatest weakness of Celldex Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 74%, being 303% points above the market average of -229%.

Input Variable	Value in 1000 USD
Assets Hidden Reserves	0
Assets, Current	410,839
Assets, Non-Current	3,074
General and Administrative Expense	20,488
Goodwill	27,190
Liabilities Hidden Reserves	0
Liabilities, Current	16,528
Liabilities, Non-Current	8,650
Other Assets	0
Other Compr. Net Income	-695
Other Expenses	1,868
Other Liabilities	0
Other Net Income	0
Property, Plant and Equipment, Net	3,551
Research and Development	53,311
Revenues	5,156

Output Variable	Value in 1000 USD
Liabilities	25,178
Assets	444,654
Expenses	75,667
Market Value Liabilities	25,178
Market Value Assets	444,654
Stockholders Equity	419,476
Net Income	-70,511
Comprehensive Net Income	-70,858
Economic Capital Ratio	74%



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai